Replies to post #237535 on Biotech Values

[bladerunner1717]

Dew, Mr. Market seems singularly unimpressed with the PFE/MYOV data in uterine fibroids. What in the PR do you see that accounts for the Market reaction?

Bladerunner

[DewDiligence]

MYOV/PFE—The new data are from an open-label extension study in a phase-3 program that has already had several remarkable successes, so I wouldn't expect the new data to have a big effect on MYOV's share price.

Do you think possibility of MYOV buyout lurks in the future by PFE?

Possible but unlikely, IMO, for the reason mentioned in #msg-160575199.